Researchers in Switzerland have developed an implant that can detect common types of cancer in the body and act as an early warning system by causing a small mole to form on skin.
This content was published on
2 minutes
ETHZ/sb
A team from Zurich’s Federal Institute of Technology (ETHZ)External link have developed a prototype implant which can be inserted under the skin. It contains a network of cells which constantly monitor calcium levels in the body. Cancer can cause calcium levels to rise in the body. The implant detects when a threshold is exceeded and triggers the production of melanin, causing a small dark mole to form.
The implant can recognise the four most common types of cancer – prostate, lung, colon and breast cancer – at a very early stage. Cancer is the main cause of death alongside cardiovascular disease in industrialised countries. However, many of those affected are only diagnosed after a tumour has developed extensively.
“Early detection increases the chance of survival significantly,” said Martin Fussenegger, Professor at the Department of Biosystems Science and Engineering at ETHZ in Basel. If breast cancer is detected early, for example, the chance of recovery is 98%. However, if the tumour is diagnosed too late, only one in four women has a good chance of recovery.
The implant is intended primarily for self-monitoring, making it very cost effective. However, the service life of such a device is limited, as encapsulated living cells last for about a year. After that, they must be inactivated and replaced.
So far, the prototype early warning device has been tested on mice and on pig skin, where it functioned reliably, the ETHZ wrote. Tests on humans are still years away.
“Continued development and clinical trials in particular are laborious and expensive, which we as a research group cannot afford,” said Fussenegger. He believes it will take another ten years of research and development for a cancer diagnosis implant to be available for sale.
Swiss football boss wants crackdown on individual hooligans
This content was published on
The head of the Swiss Football League says he prefers a harsher approach to individual hooligans rather than collective punishment measures affecting all fans.
Amherd: Council of Europe is ‘as urgently needed as ever’
This content was published on
The Swiss government emphasised on Sunday the vital role of the Strasbourg-based Council of Europe, 75 years after it was founded.
Swiss minister: Italy will back Switzerland in EU talks
This content was published on
Bern can count on the backing of Italy as it re-enters talks with the European Union on future relations, Viola Amherd says.
Student protestors at University of Lausanne continue pro-Palestine sit-in
This content was published on
Since Thursday, a hall on campus has been occupied by students calling for a boycott of Israeli academic institutions and a ceasefire in Gaza.
This content was published on
Swiss public broadcasters RTS and SRF are drastically reducing their communications via the social network X (formerly Twitter).
Israel: president of Swiss universities rejects academic boycott
This content was published on
Luciana Vaccaro, president of Swissuniversities, the umbrella group of Swiss universities, is not in favour of an academic boycott of Israeli universities.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss national cancer registry programme postponed
This content was published on
The Federal Council announced on Wednesday that the national cancer registry programme will not start until 2020, a year later than planned.
This content was published on
Preventive medicine is a big piece of the health care puzzle, yet has not always gotten the attention – or resources – it deserves.
Swiss hospitals join forces in battle against cancer
This content was published on
Fribourg's cantonal hospital is joining forces with a private clinic to tackle prostate and breast cancers. It's a first in Switzerland.
This content was published on
The company Alkopharma distributed 2,119 bottles of Thiotepa in Switzerland, costing more than CHF207,500 ($214,000), and a further 98,820 bottles in France for more than €3.2 million euros. More than half were used to treat patients, many of them children, reports the SonntagsZeitung and Le Matin Dimanche. The company falsified the expiry dates of the…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.